Research location
Fort Belvoir
Virginia, United States
Advertisement
Research activity in Fort Belvoir
Virginia, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 16 trials and 16 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Fort Belvoir
16 linked trials · page 1 of 1Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerNCT07085767 · 2025-11-03 · 1 site observation
RECRUITING
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung CancerNCT06350097 · 2024-04-29 · 1 site observation
RECRUITING
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsNCT06357533 · 2024-04-11 · 1 site observation
RECRUITING
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)NCT05501886 · 2022-12-08 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerNCT05514054 · 2022-10-04 · 1 site observation
ACTIVE_NOT_RECRUITING
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour ResectionNCT05120349 · 2022-02-21 · 1 site observation
ACTIVE_NOT_RECRUITING
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLCNCT05211895 · 2022-02-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT03778931 · 2019-05-10 · 1 site observation
COMPLETED
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLCNCT03041311 · 2017-06-29 · 1 site observation
COMPLETED
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in CancerNCT02744092 · 2016-12-13 · 1 site observation
COMPLETED
AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.NCT02511106 · 2015-10-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast CancerNCT02492711 · 2015-08-24 · 1 site observation
COMPLETED
Preventing Obesity in Military Communities-AdolescentsNCT02671292 · 2015-07-01 · 1 site observation
UNKNOWN
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung CancerNCT02093962 · 2014-06-01 · 1 site observation
TERMINATED
Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate CancerNCT02111577 · 2014-05-26 · 1 site observation
COMPLETED
Preventing Obesity in Military Communities, AdolescentsNCT02334202 · 2011-11-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.